CD43/Sialophorin Antibody (SPN/839) - IHC-Prediluted, Novus Biologicals™
Manufacturer: Novus Biologicals
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | NBP248379-Each-of-1 | In Stock | ₹ 46,636.00 |
NBP248379 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,636.00
GST (18%): ₹ 8,394.48
Total Price: ₹ 55,030.48
Antigen
CD43/Sialophorin
Classification
Monoclonal
Conjugate
Unconjugated
Formulation
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Gene Symbols
SPN
Immunogen
Recombinant full-length human CD43/Sialophorin protein (Uniprot: P16150)
Quantity
7 mL
Research Discipline
B Cell Development and Differentiation Markers, Immunology
Gene ID (Entrez)
6693
Target Species
Human
Form
Purified
Applications
Immunohistochemistry (Paraffin)
Clone
SPN/839
Dilution
Immunohistochemistry-Paraffin
Gene Alias
CD43 antigen, CD43), Galactoglycoprotein, GALGP, Leukocyte sialoglycoprotein, Sialophorin, sialophorin (gpL115, leukosialin, CD43)
Host Species
Mouse
Purification Method
Protein A or G purified
Regulatory Status
RUO
Primary or Secondary
Primary
Test Specificity
It recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.
Content And Storage
Store at 4C.
Isotype
IgG1 κ
Related Products
Description
- CD43/Sialophorin Monoclonal specifically detects CD43/Sialophorin in Human samples
- It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.